Previous close | 25.00 |
Open | 25.02 |
Bid | 14.40 x 3200 |
Ask | 0.00 x 1300 |
Day's range | 25.00 - 25.02 |
52-week range | 24.25 - 25.88 |
Volume | |
Avg. volume | 83,835 |
Market cap | 64.724B |
Beta (5Y monthly) | 1.42 |
PE ratio (TTM) | 0.49 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.59 (6.37%) |
Ex-dividend date | 24 Apr 2024 |
1y target est | N/A |
Transcendia Holdings, Inc. ("Transcendia" or the "Company"), a leader in manufacturing and converting custom engineered films, today announced it has entered into an agreement for a recapitalization transaction that will strengthen the Company's financial position and create a sustainable, long-term capital structure for the next phase of growth. The transaction will provide Transcendia with $114 million in new capital, eliminate more than $200 million of the Company's debt and further strengthe
Ms. Salka brings more than 30 years of healthcare leadership and staffing expertise, including strong C-suite, financial and ESG expertise to advance the company’s Patients-first focus and growth initiativesDURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Susan R. Salka, retired Chief Executive Officer and President
DirectBooks, a global leader in primary markets communications, announced today that Santander, Ramirez & Co. and Mischler Financial Group have joined the platform. The recent additions increase the number of underwriters participating on DirectBooks to 34 worldwide.